TWM
GILD icon

Trueblood Wealth Management’s Gilead Sciences GILD Stock Holding History

Trueblood Wealth Management’s Portfolio GILD Stock Details GILD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$379K Sell
2,998
-1,379
-32% -$182K 0.13% 184
2026
Q1 		$610K Sell
4,377
-79
-2% -$11.1K 0.24% 133
2025
Q4 		$547K Buy
+4,456
New +$542K 0.21% 142
2024
Q1 		– Sell
-4,786
Closed -$388K – 227
2023
Q4 		$388K Buy
+4,786
New +$372K 0.24% 122

Other funds holding GILD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Trueblood Wealth Management's GILD Position: Q2 2026 in Review

Trueblood Wealth Management reduced its Gilead Sciences (GILD) stake by 32% in Q2 2026, selling an estimated $182K and leaving 2,998 shares worth $379K. The position accounts for 0.13% of the portfolio, ranked #184.

Trueblood Wealth Management first reported a position in GILD in Q4 2023 and has held it in 4 quarters since. The position peaked at $610K in Q1 2026. 2,268 funds tracked by Wall St. Rank hold GILD as of Q2 2026.

  • Trueblood Wealth Management held 2,998 shares of Gilead Sciences worth $379K as of Q2 2026.
  • Trueblood Wealth Management sold 1,379 Gilead Sciences shares in Q2 2026, an estimated $182K.
  • Gilead Sciences made up 0.13% of Trueblood Wealth Management's portfolio in Q2 2026, its #184 holding.
  • Trueblood Wealth Management first reported a position in Gilead Sciences in Q4 2023 and has held it in 4 quarters since.
  • Trueblood Wealth Management's Gilead Sciences position peaked at $610K in Q1 2026.
  • 2,268 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2026.

Based on Trueblood Wealth Management's 13F filing for Q2 2026, filed 27 Jul 2026.